Kevzara phase III U.S. trial in COVID-19 patients does not meet endpoints. Sanofi + Regeneron
Sanofi and Regeneron Pharmaceuticals, Inc. announced that the . Phase III trial of Kevzara (sarilumab) 400 mg in COVID-19 patients requiring mechanical ventilation did not meet its primary… read more.